Diagnostic utility of leptin and insulin-like growth factor binding protein-2 in hepatocellular carcinoma of diabetic and non-diabetic Egyptian patients by Abouzied, Mekky M. et al.
Abouzied et al 
Trop J Pharm Res, January 2017; 16(1): 211  
 
Tropical Journal of Pharmaceutical Research January 2017; 16 (1): 211-218 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i1.28 
Original Research Article 
 
 
Diagnostic utility of leptin and insulin-like growth factor 
binding protein-2 in hepatocellular carcinoma of diabetic 
and non-diabetic Egyptian patients 
 
Mekky M Abouzied1,2*, Maiiada H Nazmy2, Randa M Mohamed2, Michael A 
Fawzy2, Heba M Eltahir1 
1Departments of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Medina, Kingdom of Saudi Arabia  
2Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61511, Egypt 
 
*For correspondence: Email: m_meky2001@yahoo.com 
 
Received: 30 June 2016        Revised accepted: 3 December 2016 
 
Abstract 
Purpose: To elucidate the possible diagnostic utility of adipokines and insulin growth factor binding 
proteins in hepatocellular carcinoma (HCC) diabetic subjects.  
Methods: Seventy five patients were divided equally into 3 groups as follows: healthy normal control 
(NC), non-diabetic hepatocellular carcinoma (HCC) and diabetic hepatocellular carcinoma (HCC-DM). 
Serum levels of leptin, insulin growth factor binding protein-2 (IGFBP-2) and alpha fetoprotein (AFP) 
were measured. Correlation and receiver operating characteristics (ROC) analysis was carried out.  
Results: HCC and HCC-DM groups showed changes in body mass index (BMI, p > 0.05 and p < 0.001 
respectively), glucose, insulin, homeostatic model assessment-insulin resistance (HOMA-IR), liver 
function tests and AFP (p < 0.001). Leptin levels increased significantly in both HCC and HCC-DM (p < 
0.001). Furthermore, IGFBP-2 showed significant increase in both groups (p < 0.001). Both leptin and 
insulin-like growth factor binding protein-2 (IGFBP-2) displayed significant positive correlation with AFP 
(p < 0.001). ROC analysis indicate different diagnostic accuracies for the tested markers for the various 
groups.  
Conclusion: Leptin and IGFBP-2 demonstrate significant potentials as diagnostic tools for HCC 
patients, especially diabetic cases, with IGFBP-2 displaying the highest diagnostic accuracy for HCC 
and HCC-DM groups.  
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Obesity and type 2 diabetes mellitus may have a 
positive association with both the risk of cancer 
and cancer-related mortality. Given the dramatic 
increase in rates of obesity and diabetes [1], this 
connection is a great public health concern. The 
exact molecular mechanisms for this association 
are yet unknown, but chronic, sustained 
hyperinsulinaemia in these insulin-resistant 
syndromes appears to play a role in the 
neoplastic transformation process [2]. A more 
detailed molecular and mechanistic 
understanding is required to interpret existing 
data. Understanding these mechanisms may 
lead to novel diagnostic and prognostic 
strategies for HCC [3]. 
 
For many years adipose tissue was believed to 
act primarily as an insulator and energy store for 
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the body, facilitating the storage of lipids to 
better enable survival during periods of fasting. It 
is now well established that adipose tissue is 
additionally a labile secretory organ, with a 
unique secretome of biologically active 
molecules. Adipokines are multifunctional protein 
molecules that are involved in several processes 
like  metabolism, inflammation, angiogenesis, 
and proliferation [4]. Adiponectin and leptin are 
the most abundant adipocytokines produced by 
adipocytes, and the best-studied molecules in 
this class so far [5]. 
 
Leptin is a 16 kDa bioactive protein encoded by 
the Ob gene, secreted from adipocytes as well 
as other tissues, which acts as a regulator of 
energy to control satiety through stimulation in 
the central nervous system as well as to 
modulate glucose and insulin homeostasis 
through activation in peripheral tissues [6].  
 
The insulin-like growth factor (IGF) system has a 
highly conserved function in mammals and plays 
a critical role in energy metabolism and cell 
renewal in response to nutrients. IGF pathway is 
not only involved in cell growth in tissue culture, 
but it is also involved in cellular proliferation, 
migration and malignant transformation. It 
comprises IGF-I and IGF-II, type I and type II 
receptors, and a family of IGF binding proteins 
(IGFBPs) that specifically bind IGFs. The IGF 
pathway revolves around 4 essential 
components [7]. The first component contains 
the IGF ligands, which include both IGF-1 and 
IGF-2. They are slightly different from insulin 
structurally by containing an additional domain, 
which could account for their dramatically 
different role in neoplasms in comparison to 
insulin [8].  
 
The IGF ligands bind to the second component 
of the IGF axis, the receptors which include IGF-
1 receptor (IGF-1R) and IGF-2 receptor (IGF-2R) 
[7]. The third component of the IGF axis refers to 
the insulin receptor substrate (IRS) and Shc 
proteins, which are the major signals 
downstream of IGF-1R activation [9].  
 
The last key component of the IGF axis consists 
of IGF binding proteins (IGFBPs). There are 6 
members of IGFBPs with high affinities for IGF-1 
and IGF-2. For instance, IGFBPs 1-4 bind both 
IGF-1 and IGF-2 with similar affinities, yet 
IGFBP-5 and 6 strongly prefer IGF- 2 as their 
ligand [10].  In contrast to IGFBP-3, other 
IGFBPs such as IGFBP-2 seem to increase the 
bioavailability of IGF ligands [7]. In the current 
study, we aim to further explore the complex 
relation between obesity, diabetes and HCC in 
addition to comparing the secretion patterns of 
leptin and IGFBP-2 in HCC diabetic and non-
diabetic patients compared to corresponding 




Seventy five patients were recruited from Minia 
National Cancer Institute, Minia, Egypt over a 
one-year period after securing ethical their 
approval. The study protocol was approved by 
the Ethics Committee of the Faculty of 
pharmacy, Minia University, Egypt (approval no. 
2014-31) and is in accordance with the 




Only patients with recently-diagnosed, 
histologically-proven HCC, and who had not yet 
received treatment were included in this study. 
Patients diagnosis was based on radiological 
imaging, laboratory tests and clinical 
investigation according to the protocol of Minia 
National Cancer Institute. Individual patient 
profiles were collected from medical records to 
determine their clinical stages. Also diabetic 
patients recently-diagnosed with biochemically-
proven HCC who had not yet received treatment 
(i.e. insulin, insulin-releasing or adiponectin-
inducing drugs) were included. Diabetes mellitus 
was confirmed by fasting glucose levels over 
126 mg/dl or two hour post-prandial glucose 




Patients who were positive for hepatitis B 
surface antigen (HBsAg) and/or anti-HCV 




Group I: 25 normal age- and sex-matched 
healthy adult patients served as normal control 
group.  
 
Group II: 25 non-diabetic, histologically-proven 
HCC patients.  
 
Group III: 25 diabetic, histologically-proven HCC 
patients.  
 
Blood samples were collected using 
venipuncture technique in glass test tubes and 
were left to clot for a period of 30 min at 37 °C. 
Samples were then centrifuged at 3,000 rpm for 
10 min. The supernatants (sera) were collected 
and stored at –80 °C.  
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Sample collection and serum glucose/insulin 
levels 
 
Venous blood (5 mL) was withdrawn from the 
subjects following 12 h overnight fast. Serum 
glucose level was measured using Stanbio kit 
(Stanbio laboratory, USA). Insulin levels were 
determined using ELISA Biosource kits according 
to the manufacturer’s instructions. 
 
Homeostasis model assessment of insulin 
resistance 
 
The index of insulin resistance estimated by the 
homeostasis model assessment (HOMA) was 
calculated using relationships between blood 
glucose (Bg, mmol/L) and insulin (I, mUI/L) levels 
according to Eq 1 [12]. 
 




Serum activities of liver enzymes alanine 
aminotransferase (ALT) and aspartate 
aminotransferase (AST) and serum levels of 
total and direct bilirubin (TB and DB) were 
measured using Randox® kits (Randox 
laboratories Ltd, USA). 
 
Enzyme-linked immunosorbent assay 
(ELISA) 
 
Serum levels of alpha-fetoprotein, leptin 
(Diagnostics Biochem Canada Inc), adiponectin, 
insulin growth factor binding proteins-2 and -3 
were measured using RayBio-Human ELISA 





Data are expressed as mean ± standard 
deviation (SD) of 25 patients in each group, 
using one-way analysis of variance (ANOVA 
test). P < 0.05 were considered as significant. 
Correlation and ROC analysis was done using 
Graph Pad Prism (version 5.00 for windows, 
GraphPad software, San Diego, California, USA) 




General characteristics and liver function tests of 
patients are shown in Table 1. HCC group 
showed a non-significant increase in BMI (p > 
0.05), while a significant decrease in fasting 
glucose levels (hypoglycaemia) was observed in 
this group (p < 0.001). In addition, HCC group 
showed significant increase in age, HOMA-IR 
and serum levels of fasting insulin, ALT, AST, 
total- and direct bilirubin (TB and DB 
respectively) when compared to normal control 
(p <0.001).  On the other hand, significant 
increase in BMI (p < 0.01), age, fasting glucose 
and insulin, ALT, AST, TB and DB (p < 0.001) 
was observed in HCC-DM group when 
compared to normal control (Table 1). 
 
AFP levels were highest in HCC-DM group and 
lowest in normal control. Its increase in both 
HCC and HCC-DM groups was statistically 
significant when compared to normal control (p < 
0.001) (Figure 1A). Both HCC and HCC-DM 
groups showed significant increase in serum 
levels of leptin when compared to normal control 
(p < 0.001) (Figure 1B). 
 
Serum IGFBP-2 level was highest in HCC-DM 
group and lowest in normal control group. Its 
level was significantly increased in both HCC 
and HCC-DM groups when compared to normal 
control (p < 0.001) (Figure 1C). Pearson’s 
correlation coefficient test between serum level 
of leptin or IGF-BP-2 versus AFP showed 
significant (p < 0.001) positive correlation 
between either serum leptin or IGFBP-2 levels 
and AFP (r = 0.9551 for leptin, and r = 0.95 for 
IGF-BP-2 respectively, Table 2 and Figure 2). 
 
Table 1: General characteristics and liver function tests 
 
Variable NC HCC HCC-DM 
Age 29.15±8.57 57.72±4.75*** 59.82±6.01*** 
Gender (M/F) 23/2 18/7 16/9 
BMI 22.19±3.03 21.72±3.29ns 26.16±3.51** 
Fasting glucose (mmol/L) 5.55±0.45 4.23±0.27*** 8.6±16.91*** 
Fasting Insulin (µIU/ml) 2.33±0.23 6.16±0.77*** 6.97±0.72*** 
HOMA-IR 0.58±0.01 1.16±0.02*** 2.67±0.04*** 
ALT (U/L) 29.33±3.29 61.33±5.05*** 103.71±11.09*** 
AST (U/mL) 29.52±6.13 69.82±11.61*** 88.32±13.7*** 
Total Bilirubin (mg/dl) 0.76±0.11 1.59±0.55*** 1.46±0.59*** 
Direct Bilirubin (mg/dl) 0.11±0.06 0.59±0.09*** 0.32±0.09*** 
NC = normal control, DM = Diabetes mellitus, HCC= Hepatocellular carcinoma. BMI = body 
weight (kg)/the square value of height (m2). HOMA-IR = Insulin (µIU/ml) x glucose 
(mmol/L)/22.4 
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Figure 1: Serum concentrations of AFP (A), Leptin (B), IGFBP-2 (C) in various groups, compared to normal 
control. Data were expressed as mean ± SD. Significant difference between groups are analysed by unpaired t-
student test, where: *** p < 0.001: highly significant, ** p < 0.01: significant, * p < 0.05: mildly significant, p > 
0.05: non-significant, NC = normal control, DM = Diabetes mellitus, HCC = hepatocellular carcinoma 
 
Table 2: Pearson correlation coefficient test between serum levels of leptin, IGF-BP-2 versus AFP. 
 
Variable AFP vs Leptin AFP vs IGFBP-2 
Pearson r 0.9551 0.9500 
95% confidence interval 0.9247 to 0.9734 0.9163 to 0.9704 
R squared 0.9123 0.9025 
P (two-tailed) p < 0.0001 p < 0.0001 
 
 
Figure 2: Pearson’s correlation coefficient test for serum levels of leptin, IGF-BP-2 versus AFP 
 
Table 3: Area under the curve (AUC), cut-off values, sensitivity and specificity for different markers 
 
Marker AUC Cut-off Sensitivity (%) Specificity Diagnostic 
HCC vs NC      
AFP (ng/ml) 0.994 >  126 100 94 97 
Leptin (ng/ml) 0.9640 > 12.7 84 94 89 
IGFBP-2 0.9806 > 2919 100 94.7 97.4 
HCC-DM vs NC      
AFP (ng/ml) 0.9945 >  126.6 100 94.7 97.4 
Leptin (ng/ml) 0.9640 > 13.6 89 94 91.5 
IGFBP-2 0.9806 > 3010 100 94.9 97.5 
     Note: Overall diagnostic accuracy is the weighted average of a test's sensitivity and specificity 
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Figure 3: Receiver Operating Characteristic (ROC) curve for AFP, Leptin, IGFBP-2 in various 
situations. A: HCC vs. normal control, B: HCC-DM vs normal control 
 
ROC analysis including area under the curve 
(AUC), cut-off values, sensitivities, specificities and 
diagnostic accuracies for different markers were 
done, and the overall diagnostic accuracy was 
calculated as the weighted average of a test's 
sensitivity and specificity. Arranging the different 
groups according to their diagnostic accuracy 
resulted in the following ranking: IGFBP-2 > AFP > 




An increased incidence of HCC in obese and 
diabetic subjects has led to the necessity to 
characterize the role of metabolic syndrome in 
liver carcinogenesis. Metabolic syndrome 
includes multiple disorders including glucose 
intolerance, hyperglycemia, Type 2 diabetes 
mellitus, overweight, high blood pressure and 
dyslipidemia [13]. In 2012, Campbell et al [14] 
conducted a large prospective cohort study 
which included over one million subjects and 
found that diabetic women and men had an 
increased risk of 1.40 (95 %CI: 1.05-1.86) and 
2.26 (95 %CI: 1.89 - 2.70) for developing HCC, 
respectively. But even if the role of impaired 
glucose metabolism is important in 
hepatocarcinogenesis, its impact on HCC natural 
history is still controversial. Recently, Howell et al 
[15] compared diabetic and-non diabetic subjects 
treated for HCC and couldn’t find a survival 
difference between both groups. In contrast, a 
meta-analysis by Wang et al [16] found that 
patients with co-existing type II DM had a shorter 
survival time and a higher risk for tumor 
recurrence after curative treatments. This study 
highlighted the important role of adipokines and 
IGFBPs in mediating the interrelation between 
obesity, type II DM and HCC, and demonstrated 
different secretion patterns and diagnostic 
utilities for these parameters in various situations 
(i.e. diabetic HCC and non-diabetic HCC 
patients).  
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Diabetic patients showed significant biochemical 
variations in BMI, glucose homeostasis, insulin 
resistance and liver function tests. These finding 
are consistent with former observations which 
explained in details the role of liver in glucose 
homeostasis and the interaction between type II 
DM and liver disease [17]. .   
 
The pathophysiological hallmarks of type 2 
diabetes mellitus are insulin resistance and β-cell 
dysfunction. There is now consensus that a 
variety of adipokines can modify both insulin 
sensitivity and secretion. Therefore they offer 
candidate mechanisms for a link between obesity 
and type 2 diabetes [18].  
 
It has been suggested that the association 
between plasma leptin and diabetes may be a 
manifestation of an underlying leptin resistance 
mediated by obesity [19]. Some studies have 
reported that there is no association between 
plasma leptin levels and diabetes [20], whereas a 
significant positive correlation between both 
conditions was reported by other groups [21]. 
However, other studies reported an inverse 
relation [22]. Also, few studies reported that the 
association between plasma leptin and DM was 
observed only in men and not in women [21]. 
Consistent with the low circulating levels of 
adiponectin observed in type II DM, adiponectin 
concentration was found to be inversely related 
to leptin, insulin resistance and central adiposity 
[23].  
 
Increasing evidence suggests that the insulin-like 
growth factor (IGF) axis may play a role in 
glucose homeostasis [24]. IGF-I shares structural 
homology and downstream signalling pathways 
with insulin, and like insulin, IGF-I can promote 
glucose and fatty acid uptake in peripheral 
tissues [25]. In the current study, IGFBP-2 levels 
were significantly increased in both HCC and 
HCC diabetic patients. Consistent with this 
finding, cross-sectional studies have found that 
individuals with impaired glucose tolerance or 
diabetes have possibly higher IGFBP-3 levels 
than healthy individuals [26]. A positive 
association between high IGFBP-3 and diabetes 
can be explained by its sequestration of IGF-I 
[27]. In addition to this effect, some IGFBPs like 
IGFBP-2 may also have important IGF-
independent, potentially beneficial effects on 
glucose uptake [28]. IGFBP-2 circulates at 
equimolar or lower molar concentrations 
compared to IGF-1, unlike hormone inhibitors 
which usually circulate in molar excess 
compared to the ligand. In vivo, IGFBP-2 has 
been shown to play a role to modulate IGF 
signalling in diabetes. The precise function of 
IGFBP-2 is poorly understood, and it is not well 
established whether it inhibits or activates IGF-1 
signalling in vivo or if it has actions independent 
of IGF [29]. 
 
Altered levels of adipokines or their cognate 
receptors in cancers can ultimately lead to an 
imbalance in downstream molecular pathways 
[30]. Leptin has been shown to increase 
proliferation, migration, and invasion of cancer 
cells [31] as well as contribute to release of 
VEGF [32]. The molecular mechanisms through 
which leptin affects cancer cell behaviour still 
require further elucidation. It is believed that 
cross-talk between adipokines as well as the 
activation of multiple pathways via activation of 
Janus-activated kinase (JAK2) and subsequent 
up regulation of Ras and PPAR-γ keep 
proliferative signalling in balance [33]. In our 
study we also aimed to elucidate the secretion 
patterns of adipokines and IGF axis and to 
compare these patterns in HCC diabetic and 
non-diabetic HCC patients.  
 
Leptin was significantly increased in HCC and 
diabetic HCC patients. This may be, in part, 
related to non-significant change in BMI in non-
diabetic HCC as well. A number of studies have 
attempted to elucidate the possible effects of 
leptin in HCC development. In patients with 
hepatocellular carcinoma, elevated leptin levels 
have been reported in comparison to normal or 
preoperative levels [34].  
 
Insulin-like growth factor binding proteins 
(IGFBPs) constitute a family of six circulating 
proteins that bind insulin-like growth factor (IGF)-
I and -II with high affinity [35].  In our study, 
serum levels of IGFBP- 2 showed significant 
increase in both diabetic and non-diabetic HCC 
patients. These data are in accordance with 
previous reports indicating that serum levels of 
IGFBP-2 were significantly higher while IGFBP-3 
levels were normal [36] or significantly lower [37] 
in patients with HCC compared to healthy 
subjects.  
 
IGFBP-2 has been considered as an inhibitory 
factor for  IGFs , particularly of IGF-II [35].  
IGFBP-2 expression changes dynamically 
showing its highest levels during the prenatal 
stages. After birth, the expression of IGFBP-2 
decreases significantly, however, IGFBP-2 is the 
second most abundant IGFBP in serum. It is also 
altered in various pathological conditions 
including HCC [38]. IGFBP-2 is not only a 
modulator of IGF/IGF receptor signalling, but 
also a pleiotropic factor which has important 
effects on cellular proliferation, motility, 
interactions with the extracellular matrix and 
transcription [29].  
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Based on the obtained data, leptin and IGFBP-2 
demonstrate significant potentials as diagnostic 
markers for diabetic HCC patients. IGFBP-2 
displayed the highest diagnostic accuracy 
followed by AFP and leptin for HCC and HCC-
DM groups. This makes it a good marker that 
can be measured in combination with AFP to 
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